Newsroom
Top Results
Sight Sciences Announces Multiple Presentations at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting
New safety and efficacy data from both retrospective and prospective studies of the OMNI Surgical System and a prospective study of the TearCare System to be presented
Sight Sciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Sight Sciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Sight Sciences Announces Pricing of Initial Public Offering
Sight Sciences Announces Pricing of Initial Public Offering
Sight Sciences Announces Substantial Crossover Raise
Funds will be used to continue clinical and commercial acceleration
Sight Sciences Appoints Donald J. Zurbay to Company’s Board of Directors
Highly accomplished industry executive brings financial and operational expertise to innovative eye care company
Sight Sciences Strengthens Its Leadership Team with Chief Operating Officer and General Counsel Hires
Industry veterans will lead scaling of company operations and processes to support OMNI Surgical System and TearCare growth
Sight Sciences Announces Publication of Historical Review of Canal Surgery in the Glaucoma Issue of Current Opinion in Ophthalmology
Sight Sciences, Inc., a growth-stage medical device company focused on transforming the treatment of glaucoma and dry eye disease, today announced that a review of the history of canal surgery in glaucoma, by Jaime Dickerson, Ph.D., and Reay Brown, M.D.
Sight Sciences Announces $30 Million Financing Led by D1 Capital Partners
MENLO PARK, Calif., March 18, 2020 /PRNewswire/ — Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the closing of an over $30 million Series E Preferred Stock financing round led by D1 Capital Partners. Proceeds will be used for continued clinical and […]